


PHARMACEUTICAL 2022

ARDELYX INC. Rank 419 of 475







PHARMACEUTICAL 2022

ARDELYX INC. Rank 419 of 475



The relative strengths and weaknesses of ARDELYX INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARDELYX INC. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 30% points. The greatest weakness of ARDELYX INC. is the variable Net Income, reducing the Economic Capital Ratio by 247% points.

The company's Economic Capital Ratio, given in the ranking table, is -508%, being 231% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	133,649
Cost of Goods Sold	1,000
Intangible Assets	0
Liabilities, Current	52,821
Liabilities, Non-Current	14,475
Other Assets	13,902
Other Compr. Net Income	-2.0
Other Expenses	4,506
Other Liabilities	0
Other Net Income	687
Property and Equipment	2,362
Research and Development	91,140
Revenues	10,097
Selling, General and Administrative Expense	72,303

Output Variable	Value in 1000 USD
Assets	149,913
Liabilities	67,296
Expenses	168,949
Stockholders Equity	82,617
Net Income	-158,165
Comprehensive Net Income	-158,166
Economic Capital Ratio	-508%

